Bio-Gate (BIG1) H1 2025 earnings summary

Executive summary

• Expanded in-house production increased value chain share and improved results despite a slight revenue decline year-over-year for H1 2025.

• Key management positions in logistics, procurement, and supply chain were filled to support growth.

• Ongoing clinical studies and product launches in medtech and wound care signal strong medium- and long-term prospects.

Financial highlights

• Revenue for H1 2025 was €3.44M, down slightly from €3.51M in H1 2024.

• EBITDA improved to -€723K from -€957K year-over-year; net loss after minorities improved to -€836K from -€1.08M.

• Material and personnel costs declined, and other operating expenses fell by nearly 20%.

• Cash and cash equivalents at period end were €174K, down from €297K at year-end 2024.

• Equity ratio dropped to 21.9% from 45.3% at year-end 2024.

Outlook and guidance

• Management expects significant revenue and earnings growth for full-year 2025, contingent on timely project execution and product commercialization.

• Continued investment in production and lab capacity is expected to further enhance value creation.